Novartis,  —

Articles by Novartis

ZOLGENSMA: The One and Only Single-Dose Treatment for SMA

Any parent who has received a spinal muscular atrophy (SMA) diagnosis for their child can tell you that early treatment is crucial. Children who receive treatment for SMA as soon as possible are more likely to achieve important motor milestones. One-time gene therapy ZOLGENSMA® (onasemnogene abeparvovec-xioi), can stop the…